Skip to content

Clinical trials

Multiple Myeloma trials in Italy

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Multiple Myeloma Country / region: Italy Clear all

275 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20002
20012
20026
20037
20042
20057
20065
20074
20086
20098
20107
201111
201211
20137
201413
20157
201616
201715
201810
201919
202014
202114
202220
202318
20248
202514
202613

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed140
Recruiting45
Active, not recruiting38
Terminated28
Unknown status16
Not yet recruiting4
Withdrawn3
Enrolling by invitation1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Celgene26
Fondazione EMN Italy Onlus17
European Myeloma Network B.V.13
Janssen Research & Development, LLC13
Fred Hutchinson Cancer Center12
Amgen11
Bristol-Myers Squibb11
Sanofi10
Novartis Pharmaceuticals9
AbbVie8

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Multiple Myeloma275
Recurrence42
Lymphoma, Non-Hodgkin22
Leukemia, Myeloid, Acute20
Hodgkin Disease19
Leukemia, Lymphocytic, Chronic, B-Cell19
Neoplasms, Plasma Cell19
Precursor Cell Lymphoblastic Leukemia-Lymphoma19
Lymphoma16
Lymphoma, Large B-Cell, Diffuse16

Trials

Showing 76 to 100 of 275. Each trial links to its page on Pharma Observatory.

175 more trials match. See them on Pharma Observatory

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.